×
Xeris Biopharma Holdings Long Term Debt 2017-2025 | XERS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Xeris Biopharma Holdings long term debt from 2017 to 2025. Long term debt can be defined as the sum of all long term debt fields.
View More
Xeris Biopharma Holdings Long Term Debt 2017-2025 | XERS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Xeris Biopharma Holdings long term debt from 2017 to 2025. Long term debt can be defined as the sum of all long term debt fields.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$81.7B
Zoetis (ZTS)
$66.3B
Daiichi Sankyo, - (DSNKY)
$46.4B
Takeda Pharmaceutical (TAK)
$43.3B
BeOne Medicines - (ONC)
$32.9B
Sandoz Group AG (SDZNY)
$25.9B
Summit Therapeutics (SMMT)
$19.8B
Merck (MKKGY)
$16.5B
Shionogi (SGIOY)
$14.3B
Neurocrine Biosciences (NBIX)
$13.5B
United Therapeutics (UTHR)
$12.7B
Orion OYJ (ORINY)
$11.5B
IPSEN (IPSEY)
$10.8B
Stevanato Group S.p.A (STVN)
$7.6B
Grifols, S.A (GRFS)
$7.5B
Corcept Therapeutics (CORT)
$7.4B
Ionis Pharmaceuticals (IONS)
$6.9B
Madrigal Pharmaceuticals (MDGL)
$6.4B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.3B
Hypermarcas (HYPMY)
$3.1B
Crinetics Pharmaceuticals (CRNX)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
NewAmsterdam Pharma (NAMS)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.2B
Ocular Therapeutix (OCUL)
$1.9B
Endo (NDOI)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.8B